Stay updated on Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Sign up to get notified when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.

Latest updates to the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now displays a Last Update Posted timestamp in the Study Record Dates section, and the Last Update Posted (Estimated) field has been removed.SummaryDifference0.0%

- Check22 days agoChange DetectedMinor version update: Revision changed from v3.3.3 to v3.3.4, with no changes to core content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check29 days agoChange DetectedLocations updated: two new sites in Tokyo (tabashi City, 173-0015 and Setagaya-Ku, 156-0057) were added and a Tampa site was withdrawn, bringing the total locations to 411.SummaryDifference0.2%

- Check50 days agoChange DetectedThe ADEPT-3 study added numerous new locations across the globe, including sites in China, Argentina, and the United States (e.g., 7021, 7023–7028). The total number of study locations now reaches 409.SummaryDifference3%

- Check71 days agoChange DetectedNew locations and site details were added (e.g., Site 4215 in Iława, Poland and Site 1246 in Naples, FL) and investigator contacts updated. The total number of reported locations now stands at 397.SummaryDifference0.7%

- Check80 days agoChange DetectedAdded 'Last Update Posted (Estimated)' under Study Record Dates. Removed the government funding lapse notice.SummaryDifference0.1%

Stay in the know with updates to Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.